Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BTAI Stock Summary
Top 10 Correlated ETFs
BTAI
In the News
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy.
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2023 financial results on Tues., March 12, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company's financial results and provide a general business update.
Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?
BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Friday after the commercial-stage biopharmaceutical company announced a proposed underwritten public offering for its shares. This public offering includes $60 million shares of BTAI stock.
7 Penny Stocks With Low Floats and High Short Interest
There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.
BioXcel Therapeutics stock plummets as 3Q earnings fall short of expectations
BioXcel Therapeutics Inc (NASDAQ:BTAI) shares fell almost 35% after it reported a revenue miss and greater than forecast loss for the third quarter. The New Haven, Connecticut-based biopharmaceutical company reported sales of $341,000, up from $137,000 in the year-ago quarter but below estimates of $840,000.
5 Most Active Penny Stocks Today & Why They're Moving Now
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
Penny Stocks To Buy Today? 4 To Watch Now
Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.
4 Penny Stocks To Watch Today With Big News, Time To Buy?
Trading penny stocks can be a risky endeavor, but having access to quality news and information can help mitigate some of that risk. As an investor or trader, it's critical to understand how news events can impact penny stocks and how to use news to your advantage when developing your trading strategy.
3 Penny Stocks To Buy For Under $5, Are They Worth It?
Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroots.
5 Hot Penny Stocks To Watch In The Stock Market Today
Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events is important.
BTAI Financial details
BTAI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.01 | 0.05 | |
Net income per share | -1.99 | -3.78 | -4.04 | -6.13 | -6.15 | |
Operating cash flow per share | -1.67 | -3.06 | -3.12 | -4.83 | -5.32 | |
Free cash flow per share | -1.73 | -3.07 | -3.13 | -4.84 | -5.32 | |
Cash per share | 1.99 | 9.83 | 8.83 | 6.92 | 2.24 | |
Book value per share | 1.65 | 9.53 | 8.41 | 2.74 | -1.94 | |
Tangible book value per share | 1.65 | 9.53 | 8.41 | 2.74 | -1.94 | |
Share holders equity per share | 1.65 | 9.53 | 8.41 | 2.74 | -1.94 | |
Interest debt per share | 0.07 | 0.08 | 0.05 | 3.65 | 3.93 | |
Market cap | 237.98M | 1B | 536.16M | 601.76M | 85.93M | |
Enterprise value | 206.59M | 790.27M | 304.59M | 502.19M | 121.75M | |
P/E ratio | -7.36 | -12.22 | -5.03 | -3.5 | -0.48 | |
Price to sales ratio | 0 | 0 | 0 | 1.6K | 62.27 | |
POCF ratio | -8.72 | -15.1 | -6.53 | -4.45 | -0.55 | |
PFCF ratio | -8.45 | -15.03 | -6.49 | -4.44 | -0.55 | |
P/B Ratio | 8.85 | 4.85 | 2.42 | 7.84 | -1.52 | |
PTB ratio | 8.85 | 4.85 | 2.42 | 7.84 | -1.52 | |
EV to sales | 0 | 0 | 0 | 1.34K | 88.22 | |
Enterprise value over EBITDA | -6.06 | -9.6 | -2.85 | -3.19 | -0.73 | |
EV to operating cash flow | -7.57 | -11.91 | -3.71 | -3.71 | -0.79 | |
EV to free cash flow | -7.34 | -11.85 | -3.69 | -3.71 | -0.79 | |
Earnings yield | -0.14 | -0.08 | -0.2 | -0.29 | -2.08 | |
Free cash flow yield | -0.12 | -0.07 | -0.15 | -0.23 | -1.8 | |
Debt to equity | 0.04 | 0.01 | 0.01 | 1.23 | -1.79 | |
Debt to assets | 0.03 | 0.01 | 0.01 | 0.46 | 1.37 | |
Net debt to EBITDA | 0.92 | 2.57 | 2.17 | 0.63 | -0.21 | |
Current ratio | 4.03 | 18.33 | 13.98 | 6.17 | 2.65 | |
Interest coverage | 0 | -3.05K | -2.67K | -19.44 | -12.59 | |
Income quality | 0.83 | 0.81 | 0.77 | 0.82 | 0.87 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 183.36 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 243.3 | 61.11 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.37 | -0.01 | |
Capex to depreciation | -5.58 | -1.68 | -1.5 | -0.43 | -0.06 | |
Stock based compensation to revenue | 0 | 0 | 0 | 46.23 | 13.49 | |
Graham number | 8.59 | 28.48 | 27.65 | 19.45 | 16.38 | |
ROIC | -1.13 | -0.39 | -0.48 | -0.96 | -3.73 | |
Return on tangible assets | -0.89 | -0.37 | -0.45 | -0.83 | -2.43 | |
Graham Net | 1.41 | 9.22 | 8.16 | 2.35 | -2.2 | |
Working capital | 25.64M | 205.22M | 216.3M | 169.97M | 44.88M | |
Tangible asset value | 26.9M | 206.7M | 221.67M | 76.78M | -56.51M | |
Net current asset value | 24.61M | 203.83M | 215.2M | 73.79M | -58.07M | |
Invested capital | 0.04 | 0.01 | 0.01 | 1.23 | -1.79 | |
Average receivables | 57.5K | 0 | 0 | 124K | 159.5K | |
Average payables | 3.28M | 4.47M | 4.33M | 7.45M | 11.94M | |
Average inventory | 0 | 0 | 0 | 992.5K | 1.99M | |
Days sales outstanding | 0 | 0 | 0 | 241.39 | 18.78 | |
Days payables outstanding | 11.59K | 7.73K | 5.75K | 186.66K | 3.96K | |
Days of inventory on hand | 0 | 0 | 0 | 36.23K | 576.76 | |
Receivables turnover | 0 | 0 | 0 | 1.51 | 19.44 | |
Payables turnover | 0.03 | 0.05 | 0.06 | 0 | 0.09 | |
Inventory turnover | 0 | 0 | 0 | 0.01 | 0.63 | |
ROE | -1.2 | -0.4 | -0.48 | -2.24 | 3.17 | |
Capex per share | -0.05 | -0.01 | -0.02 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
Net income per share | -2.07 | -1.78 | -1.83 | -1.72 | -0.76 | |
Operating cash flow per share | -1.38 | -1.83 | -1.31 | -1.28 | 0 | |
Free cash flow per share | -1.38 | -1.83 | -1.31 | -1.28 | 0 | |
Cash per share | 6.9 | 5.78 | 4.37 | 3.07 | 0 | |
Book value per share | 2.74 | 1.85 | 0.2 | -1.39 | 0 | |
Tangible book value per share | 2.74 | 1.85 | 0.2 | -1.39 | 0 | |
Share holders equity per share | 2.74 | 1.85 | 0.2 | -1.39 | 0 | |
Interest debt per share | 3.46 | 3.48 | 3.46 | 3.53 | 0 | |
Market cap | 602.9M | 533.97M | 194.39M | 74.05M | 86.87M | |
Enterprise value | 503.33M | 464.54M | 164.64M | 83.71M | 0 | |
P/E ratio | -2.59 | -2.62 | -0.91 | -0.37 | -0.98 | |
Price to sales ratio | 2.53K | 2.59K | 425.35 | 217.15 | 231.05 | |
POCF ratio | -15.6 | -10.2 | -5.09 | -1.97 | 0 | |
PFCF ratio | -15.6 | -10.2 | -5.09 | -1.97 | 0 | |
P/B Ratio | 7.85 | 10.07 | 33.15 | -1.82 | 0 | |
PTB ratio | 7.85 | 10.07 | 33.15 | -1.82 | 0 | |
EV to sales | 2.11K | 2.26K | 360.25 | 245.48 | 0 | |
Enterprise value over EBITDA | -9.7 | -9.4 | -3.28 | -1.95 | 0 | |
EV to operating cash flow | -13.03 | -8.87 | -4.31 | -2.23 | 0 | |
EV to free cash flow | -13.03 | -8.87 | -4.31 | -2.23 | 0 | |
Earnings yield | -0.1 | -0.1 | -0.28 | -0.68 | -0.26 | |
Free cash flow yield | -0.06 | -0.1 | -0.2 | -0.51 | 0 | |
Debt to equity | 1.23 | 1.81 | 16.68 | -2.46 | 0 | |
Debt to assets | 0.46 | 0.53 | 0.7 | 1 | 0 | |
Net debt to EBITDA | 1.92 | 1.4 | 0.59 | -0.22 | 0 | |
Current ratio | 6.17 | 6.16 | 3.98 | 2.51 | 0 | |
Interest coverage | -18.11 | -15.21 | -16.08 | -14.85 | -5.79 | |
Income quality | 0.7 | 0.99 | 0.71 | 0.74 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 86.82 | 114.54 | 46.09 | 62.62 | 0 | |
Research and developement to revenue | 136.38 | 134.95 | 59.02 | 57.53 | 26.42 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | -0.04 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -0.25 | 0 | 0 | |
Stock based compensation to revenue | 19.11 | 23.67 | 13.4 | 11.77 | 0 | |
Graham number | 11.29 | 8.62 | 2.88 | 7.34 | 0 | |
ROIC | -0.33 | -0.33 | -0.54 | -0.86 | 0 | |
Return on tangible assets | -0.28 | -0.28 | -0.38 | -0.5 | 0 | |
Graham Net | 2.35 | 1.38 | -0.19 | -1.69 | 0 | |
Working capital | 169.97M | 148.51M | 103.49M | 59.33M | 0 | |
Tangible asset value | 76.78M | 53.01M | 5.86M | -40.61M | 0 | |
Net current asset value | 73.79M | 50.17M | 4M | -42.32M | 0 | |
Invested capital | 1.23 | 1.81 | 16.68 | -2.46 | 0 | |
Average receivables | 2.88M | 265.5K | 357K | 583K | 0 | |
Average payables | 8.05M | 8.99M | 9.47M | 10.94M | 0 | |
Average inventory | 1.7M | 1.97M | 1.94M | 1.97M | 0 | |
Days sales outstanding | 93.78 | 123.64 | 84.88 | 193.99 | 0 | |
Days payables outstanding | 102.28K | 77.42K | 38.78K | 1.88K | 0 | |
Days of inventory on hand | 19.85K | 19.52K | 6.66K | 354.73 | 0 | |
Receivables turnover | 0.96 | 0.73 | 1.06 | 0.46 | 0 | |
Payables turnover | 0 | 0 | 0 | 0.05 | 0 | |
Inventory turnover | 0 | 0 | 0.01 | 0.25 | 0 | |
ROE | -0.76 | -0.96 | -9.13 | 1.24 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BTAI Frequently Asked Questions
What is BioXcel Therapeutics, Inc. stock symbol ?
BioXcel Therapeutics, Inc. is a US stock , located in New haven of Ct and trading under the symbol BTAI
Is BioXcel Therapeutics, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $34. The lowest prediction is $4 and the highest is $73
What is BTAI stock prediction ?
What is BioXcel Therapeutics, Inc. stock quote today ?
BioXcel Therapeutics, Inc. stock price is $2.82 today.
Is BioXcel Therapeutics, Inc. stock public?
Yes, BioXcel Therapeutics, Inc. is a publicly traded company.